Hepatocellular carcinoma (HCC) is an epithelial cancer that originates from hepatocytes and it is the most common primary malignant tumor of the liver. Till now the prognosis of HCC patients is generally poor. The molecular mechanism giving rise to HCC development and recurrence is still largely unknown. MicroRNA-31 (miR-31) is among the most commonly altered microRNAs in human cancers, and alternations of miR-31 expression were reported to play pivotal roles in tumorigenesis and tumor progression.
METHODS
: In this work, the primary biological function of miR-31 in HCC tumorigenesis was investigated.
RESULTS
: Our data showed that overexpression of miR-31 induced markedly inhibition of HCC cell proliferation, migration in vitro and inhibited xenograft tumor growth in vivo. One target gene of miR-31, NDRG3, was also demonstrated indispensable for HCC cell survival. Furthermore, miR-31 and NDRG3 were both essential for HCC cell drug resistance in adriamycin.
CONCLUSIONS
: We conclude that miR-31 is a crucial regulator in hepatocellular carcinoma, miR-31 and its target gene NDRG3 may be potential therapeutic targets for HCC treatment in the future.
ParkinD.M., BrayF., FerlayJ. and PisaniP., Estimating the world cancer burden: Globocan 2000, Int J Cancer94 (2001), 153-6.
2.
DhanasekaranR., LimayeA. and CabreraR., Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics, Hepat Med4 (2012), 19-37.
3.
CalvisiD.F., LaduS., GordenA., FarinaM., LeeJ.S., ConnerE.A., SchroederI., FactorV.M. and ThorgeirssonS.S., Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma, J Clin Invest117 (2007), 2713-22.
4.
MemeoR., de BlasiV., CherkaouiZ., DehlawiA., De' AngelisN., PiardiT., SommacaleD., MarescauxJ., MutterD. and PessauxP., New Approaches in Locoregional Therapies for Hepatocellular Carcinoma, J Gastrointest Cancer47 (2016), 239-46.
5.
ChoY.K., KimJ.K., KimM.Y., RhimH. and HanJ.K., Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies, Hepatology49 (2009), 453-9.
6.
YeoW., MokT.S., ZeeB., LeungT.W., LaiP.B., LauW.Y., KohJ., MoF.K., YuS.C., ChanA.T., HuiP., MaB., LamK.C., HoW.M., WongH.T., TangA. and JohnsonP.J., A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma, J Natl Cancer Inst97 (2005), 1532-8.
7.
GishR.G., PortaC., LazarL., RuffP., FeldR., CroitoruA., FeunL., JeziorskiK., LeightonJ., GalloJ. and KennealeyG.T., Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin, J Clin Oncol25 (2007), 3069-75.
8.
LiL., WeiX.H., PanY.P., LiH.C., YangH., HeQ.H., PangY., ShanY., XiongF.X., ShaoG.Z. and ZhouR.L., LAPTM4B: A novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling, Oncogene29 (2010), 5785-95.
9.
WangX.Q., OngkekoW.M., ChenL., YangZ.F., LuP., ChenK.K., LopezJ.P., PoonR.T. and FanS.T., Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway, Hepatology52 (2010), 528-39.
10.
TsangW.P. and KwokT.T., Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells, Oncogene26 (2007), 4877-81.
11.
AllerS.G., YuJ., WardA., WengY., ChittaboinaS., ZhuoR., HarrellP.M., TrinhY.T., ZhangQ., UrbatschI.L. and ChangG., Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding, Science323 (2009), 1718-22.
12.
BroxtermanH.J., GotinkK.J. and VerheulH.M., Understanding the causes of multidrug resistance in cancer: A comparison of doxorubicin and sunitinib, Drug Resist Updat12 (2009), 114-26.
13.
ShuklaG.C., SinghJ. and BarikS., MicroRNAs: Processing, maturation, target recognition and regulatory functions, Mol Cell Pharmacol3 (2011), 83-92.
14.
HungC.H., ChiuY.C., ChenC.H. and HuT.H., MicroRNAs in hepatocellular carcinoma: Carcinogenesis, progression, and therapeutic target, Biomed Res Int2014 (2014), 486407.
15.
XiongG., WangY., DingQ. and YangL., Hsa-mir-1269 genetic variant contributes to hepatocellular carcinoma susceptibility through affecting SOX6, Am J Transl Res7 (2015), 2091-8.
16.
LiuL., QuW. and ZhongZ., Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC, Int J Clin Exp Pathol8 (2015), 5609-13.
17.
TangB., LeiB., QiG., LiangX., TangF., YuanS., WangZ., YuS. and HeS., MicroRNA-155-3p promotes hepatocellular carcinoma formation by suppressing FBXW7 expression, J Exp Clin Cancer Res35 (2016), 93.
18.
GiannelliG., BergaminiC., FransveaE., MarinosciF., QuarantaV. and AntonaciS., Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion, Lab Invest81 (2001), 613-27.
19.
FornariF., GramantieriL., GiovanniniC., VeroneseA., FerracinM., SabbioniS., CalinG.A., GraziG.L., CroceC.M., TavolariS., ChiecoP., NegriniM. and BolondiL., MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells, Cancer Res69 (2009), 5761-7.
20.
FornariF., MilazzoM., ChiecoP., NegriniM., CalinG.A., GraziG.L., PollutriD., CroceC.M., BolondiL. and GramantieriL., MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells, Cancer Res70 (2010), 5184-93.
21.
SarkarF.H., LiY., WangZ., KongD. and AliS., Implication of microRNAs in drug resistance for designing novel cancer therapy, Drug Resist Updat13 (2010), 57-66.
22.
WangZ., LiY., AhmadA., AzmiA.S., KongD., BanerjeeS. and SarkarF.H., Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance, Drug Resist Updat13 (2010), 109-18.
23.
MengF., HensonR., LangM., WehbeH., MaheshwariS., MendellJ.T., JiangJ., SchmittgenT.D. and PatelT., Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines, Gastroenterology130 (2006), 2113-29.
24.
LaurilaE.M. and KallioniemiA., The diverse role of miR-31 in regulating cancer associated phenotypes, Genes Chromosomes Cancer52 (2013), 1103-13.
25.
RuomingW., ZhenY., TengtengZ. and JishengH., Tumor suppressor microRNA-31 inhibits gastric carcinogenesis by targeting Smad4 and SGPP2, Cancer Gene Ther22 (2015), 564-72.
XuT., QinL., ZhuZ., WangX., LiuY., FanY., ZhongS., ZhangX., XiaL., XuC. and ShenZ., MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin alpha5, Oncotarget7 (2016), 27445-57.
28.
ZhouR.J., XuX.Y., LiuB.X., DaiW.Z., CaiM.Q., BaiC.F., ZhangX.F., WangL.M., LinL., JiaS.Z. and WangW.H., Growth-inhibitory and chemosensitizing effects of microRNA-31 in human glioblastoma multiforme cells, Int J Mol Med36 (2015), 1159-64.
29.
YangC., WangY., HaoC., YuanZ., LiuX., YangF., JiangH., JiangX., ZhouP. and DingK., IER5 promotes irradiation- and cisplatin-induced apoptosis in human hepatocellular carcinoma cells, Am J Transl Res8 (2016), 1789-98.
30.
YamanakaN., OkamotoE., ToyosakaA., MitunobuM., FujiharaS., KatoT., FujimotoJ., OriyamaT., FurukawaK. and KawamuraE., Prognostic factors after hepatectomy for hepatocellular carcinomas. A univariate and multivariate analysis, Cancer65 (1990), 1104-10.
31.
XuH., MaJ., ZhengJ., WuJ., QuC., SunF. and XuS., MiR-31 functions as a tumor suppressor in lung adenocarcinoma mainly by targeting HuR, Clin Lab62 (2016), 711-8.
32.
RajbhandariR., McFarlandB.C., PatelA., GerigkM., GrayG.K., FehlingS.C., BredelM., BerbariN.F., KimH., MarksM.P., MearesG.P., SinhaT., ChuangJ., BenvenisteE.N. and NozellS.E., Loss of tumor suppressive microRNA-31 enhances TRADD/NF-kappaB signaling in glioblastoma, Oncotarget6 (2015), 17805-16.
33.
ZhangX.B., SongL., WenH.J., BaiX.X., LiZ.J. and MaL.J., Upregulation of microRNA-31 targeting integrin alpha5 suppresses tumor cell invasion and metastasis by indirectly regulating PI3K/AKT pathway in human gastric cancer SGC7901 cells, Tumour Biol37 (2016), 8317-25.
34.
XuY., XiaF., MaL., ShanJ., ShenJ., YangZ., LiuJ., CuiY., BianX., BieP. and QianC., MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest, Cancer Lett310 (2011), 160-9.
